Section 232 pharmaceutical tariffs take effect for all remaining importers

As of 12:01 a.m. Eastern Time on September 29, 2026, the Section 232 tariffs on imported patented pharmaceuticals and pharmaceutical ingredients apply to all remaining importers, completing a rollout that began earlier for companies listed in Annex III of the April 2, 2026 presidential proclamation ^[2]. The headline rate is a 100% ad valorem duty on products listed in Annex I, unless a specific exception applies ^[1][2].

What the tariff actually covers

The proclamation targets patented, branded medicines and their active pharmaceutical ingredients (APIs) and key starting materials ^[1][2]. It cites Commerce Department findings, based on FDA data, that as of 2025 roughly 53% of patented pharmaceutical products distributed in the US are produced outside the country, and that only about 15% of patented APIs by volume are made domestically for the US market ^[1][2].

Generics and biosimilars, and their ingredients, are not tariffed at this time ^[1][2]. Commerce is to report within one year on whether further action on generics is warranted ^[2]. Imports of US-origin pharmaceutical products are not subject to the tariffs, and duty drawback is available ^[2].

The discounts that blunt the 100% rate

Few large manufacturers are expected to pay the full rate, because the proclamation builds in several off-ramps ^[1][2]:

• Companies with onshoring plans approved by the Secretary of Commerce pay 20%, a rate that jumps to 100% on April 2, 2030 ^[1][2].
• Companies that have executed, or are actively negotiating, most-favored-nation (MFN) pricing agreements with the Department of Health and Human Services, combined with onshoring commitments, pay 0% through January 20, 2029 ^[1][2].
• Products of the European Union, Japan, South Korea, and Switzerland and Liechtenstein are capped at 15%, unless a lower rate applies ^[1][2]. Products of the United Kingdom are at 10%, which may drop to 0% under a future bilateral pricing agreement announced in the Federal Register ^[1][2].
• A 0% rate can apply to categories including orphan-only drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, CBRN countermeasures and animal-health products, subject to determinations by the Secretary ^[1][2].

If more than one rate could apply, the lowest one governs ^[2]. Customs and Border Protection will administer the tariffs and may request information from importers to verify eligibility ^[2].

Why it matters for patients

GLP-1 medicines such as semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo) are patented, branded drugs, which is the category this action targets ^[1][2]. But the sources here do not identify specific products, companies or Annex listings, so whether any particular GLP-1 product or its API faces a tariff — and at what rate — is not established by these documents. That depends on the Annex I product list, the country of manufacture, and whether the maker has an approved onshoring plan or an MFN pricing agreement, none of which is detailed in the sources reviewed ^[1][2].

The practical point is that tariffs are paid by the importer, not the pharmacy or the patient, and the proclamation does not set US drug prices or change insurance coverage ^[1][2]. What it does is change the cost of moving finished drugs and ingredients across the border, and it ties relief directly to two things patients have a stake in: building US manufacturing capacity and signing MFN pricing agreements that the administration says will make medicines "more accessible and affordable in the United States" ^[1].

The proclamation also leaves generics and biosimilars untouched for now, which matters for the compounded and generic corners of the market ^[1][2]. How much, if any, of the tariff cost eventually shows up in list prices, cash-pay programs or supply is not addressed in these sources.

What happens next

• By April 2, 2027: Commerce is due to report on whether to extend action to generic drugs and their ingredients ^[2].
• January 20, 2029: The 0% rate for companies with MFN pricing plus onshoring commitments expires as written ^[1][2].
• April 2, 2030: The 20% onshoring rate rises to 100% ^[1][2].

Rate changes for the UK, and any new specialty carve-outs, are to be announced through Federal Register notices ^[1][2].